Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
99.41
+3.52 (3.67%)
At close: Nov 14, 2025, 4:00 PM EST
99.00
-0.41 (-0.41%)
After-hours: Nov 14, 2025, 6:57 PM EST
Rhythm Pharmaceuticals Revenue
Rhythm Pharmaceuticals had revenue of $51.30M in the quarter ending September 30, 2025, with 54.28% growth. This brings the company's revenue in the last twelve months to $174.33M, up 54.92% year-over-year. In the year 2024, Rhythm Pharmaceuticals had annual revenue of $130.13M with 68.06% growth.
Revenue (ttm)
$174.33M
Revenue Growth
+54.92%
P/S Ratio
36.30
Revenue / Employee
$616,021
Employees
283
Market Cap
6.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 130.13M | 52.70M | 68.06% |
| Dec 31, 2023 | 77.43M | 53.79M | 227.56% |
| Dec 31, 2022 | 23.64M | 20.48M | 649.46% |
| Dec 31, 2021 | 3.15M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
RYTM News
- 5 days ago - Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025 - GlobeNewsWire
- 8 days ago - Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity - GlobeNewsWire
- 10 days ago - Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program - GlobeNewsWire
- 11 days ago - Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 25 days ago - Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - GlobeNewsWire
- 7 weeks ago - Rhythm Pharmaceuticals, Inc. - Special Call - Seeking Alpha
- 2 months ago - Rhythm Pharmaceuticals, Inc. (RYTM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha